Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib trial of APR-246 in ovarian cancer.
October 10, 2016 03:00 ET
|
Karolinska Development AB
Efficacy and safety data for APR-246 in high grade serous ovarian cancer presented at ESMO 2016 annual meeting
Details from the Aprea announcement follow:
The Phase Ib clinical study...
Ändring av antalet aktier och röster i Karolinska Development
September 30, 2016 03:00 ET
|
Karolinska Development AB
Idag, den sista handelsdagen i månaden, finns totalt 53.464.998 utestående aktier och 66.992.880 röster i Karolinska Development. Av dessa är 1.503.098 aktier av serie A med 15.030.980 röster och...
Change of number of shares and votes in Karolinska Development
September 30, 2016 03:00 ET
|
Karolinska Development AB
Today, the last trading day of the month, there are in total 53,464,998 shares outstanding which in total have 66,992,880 votes in Karolinska Development. Of these, 1,503,098 are series A...
Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin
September 27, 2016 02:00 ET
|
Karolinska Development AB
Dilafor’s largest existing shareholder, KDev Investments (an investment fund jointly owned by Karolinska Development (Nasdaq Stockholm: KDEV) and Rosetta Capital, also participated in this round. As...
Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
September 20, 2016 03:42 ET
|
Karolinska Development AB
Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million people worldwide. Mutations in alpha-synuclein are strongly linked to development of Parkinson’s...
Stockholm September 5, 2016, Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.
September 05, 2016 02:00 ET
|
Karolinska Development AB
This preliminary data is part of a larger retrospective study which will be published and presented once completed. The preliminary data will be available in the OssDsign booth (#1)...
Karolinska Development: Interim Report for January-June 2016
August 31, 2016 06:06 ET
|
Karolinska Development AB
Jim Van heusden, CEO, comments: “In the first half of 2016 Karolinska Development achieved three key developments within our portfolio companies: we secured additional financing; ensured continued...
Karolinska Development: Delårsrapport för januari - juni 2016
August 31, 2016 06:06 ET
|
Karolinska Development AB
Jim Van heusden, CEO, kommenterar: “Under första halvåret 2016 uppnådde Karolinska Development tre viktiga mål tillsammans med portföljbolagen: ytterligare finansiering säkrades, en fortsatt...
Karolinska Development: Interim Report for January-June 2016
August 31, 2016 02:42 ET
|
Karolinska Development AB
Jim Van heusden, CEO, comments: “In the first half of 2016 Karolinska Development achieved three key developments within our portfolio companies: we secured additional financing; ensured continued...
Karolinska Development: Delårsrapport för januari - juni 2016
August 31, 2016 02:42 ET
|
Karolinska Development AB
Jim Van heusden, CEO, kommenterar: “Under första halvåret 2016 uppnådde Karolinska Development tre viktiga mål tillsammans med portföljbolagen: ytterligare finansiering säkrades, en fortsatt...